Cargando…
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
BACKGROUND: Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877435/ https://www.ncbi.nlm.nih.gov/pubmed/29381682 http://dx.doi.org/10.1038/bjc.2017.474 |
_version_ | 1783310697718874112 |
---|---|
author | Qu, Sifeng Ci, Xinpei Xue, Hui Dong, Xin Hao, Jun Lin, Dong Clermont, Pier-Luc Wu, Rebecca Collins, Colin C Gout, Peter W Wang, Yuzhuo |
author_facet | Qu, Sifeng Ci, Xinpei Xue, Hui Dong, Xin Hao, Jun Lin, Dong Clermont, Pier-Luc Wu, Rebecca Collins, Colin C Gout, Peter W Wang, Yuzhuo |
author_sort | Qu, Sifeng |
collection | PubMed |
description | BACKGROUND: Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived therapeutic, led to marked synergistic tumour growth inhibition. Here, we investigated the effect of docetaxel+Aneustat on metastasis. METHODS: C4-2 cells were incubated with docetaxel, Aneustat and docetaxel+Aneustat to assess effects on cell migration. The LTL-313H model, similarly treated, was analysed for effects on lung micro-metastasis and kidney invasion. The LTL-313H gene expression profile was compared with profiles of PCa patients (obtained from Oncomine) and subjected to IPA to determine involvement of cancer driver genes. RESULTS: Docetaxel+Aneustat markedly inhibited C4-2 cell migration and LTL-313H lung micro-metastasis/kidney invasion. Oncomine analysis indicated that treatment with docetaxel+Aneustat was associated with improved patient outcome. The drug combination markedly downregulated expression of cancer driver genes such as FOXM1 (and FOXM1-target genes). FOXM1 overexpression reduced the anti-metastatic activity of docetaxel+Aneustat. CONCLUSIONS: Docetaxel+Aneustat can inhibit PCa tissue invasion and metastasis. This activity appears to be based on reduced expression of cancer driver genes such as FOXM1. Use of docetaxel+Aneustat may provide a new, more effective regimen for therapy of metastatic PCa. |
format | Online Article Text |
id | pubmed-5877435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58774352018-04-04 Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer Qu, Sifeng Ci, Xinpei Xue, Hui Dong, Xin Hao, Jun Lin, Dong Clermont, Pier-Luc Wu, Rebecca Collins, Colin C Gout, Peter W Wang, Yuzhuo Br J Cancer Translational Therapeutics BACKGROUND: Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived therapeutic, led to marked synergistic tumour growth inhibition. Here, we investigated the effect of docetaxel+Aneustat on metastasis. METHODS: C4-2 cells were incubated with docetaxel, Aneustat and docetaxel+Aneustat to assess effects on cell migration. The LTL-313H model, similarly treated, was analysed for effects on lung micro-metastasis and kidney invasion. The LTL-313H gene expression profile was compared with profiles of PCa patients (obtained from Oncomine) and subjected to IPA to determine involvement of cancer driver genes. RESULTS: Docetaxel+Aneustat markedly inhibited C4-2 cell migration and LTL-313H lung micro-metastasis/kidney invasion. Oncomine analysis indicated that treatment with docetaxel+Aneustat was associated with improved patient outcome. The drug combination markedly downregulated expression of cancer driver genes such as FOXM1 (and FOXM1-target genes). FOXM1 overexpression reduced the anti-metastatic activity of docetaxel+Aneustat. CONCLUSIONS: Docetaxel+Aneustat can inhibit PCa tissue invasion and metastasis. This activity appears to be based on reduced expression of cancer driver genes such as FOXM1. Use of docetaxel+Aneustat may provide a new, more effective regimen for therapy of metastatic PCa. Nature Publishing Group 2018-03-20 2018-01-30 /pmc/articles/PMC5877435/ /pubmed/29381682 http://dx.doi.org/10.1038/bjc.2017.474 Text en Copyright © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Translational Therapeutics Qu, Sifeng Ci, Xinpei Xue, Hui Dong, Xin Hao, Jun Lin, Dong Clermont, Pier-Luc Wu, Rebecca Collins, Colin C Gout, Peter W Wang, Yuzhuo Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title_full | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title_fullStr | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title_full_unstemmed | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title_short | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
title_sort | treatment with docetaxel in combination with aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877435/ https://www.ncbi.nlm.nih.gov/pubmed/29381682 http://dx.doi.org/10.1038/bjc.2017.474 |
work_keys_str_mv | AT qusifeng treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT cixinpei treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT xuehui treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT dongxin treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT haojun treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT lindong treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT clermontpierluc treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT wurebecca treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT collinscolinc treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT goutpeterw treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer AT wangyuzhuo treatmentwithdocetaxelincombinationwithaneustatleadstopotentinhibitionofmetastasisinapatientderivedxenograftmodelofadvancedprostatecancer |